According to Nast et al., infliximab, all anti-IL-17 (ixekizumab, secukinumab, bimekizumab, and brodalumab), and anti-IL23 drugs (risankizumab and guselkumab, but not tidrakizumab), were superior to ustekinumab in terms of reaching Psoriasis Area Severity Index (PASI) 90 [29]. Here, IL37 is linked to psoriasis.